Samsung Biologics Co. is seeking to raise as much as $2 billion from a South Korean initial public offering, taking an important step toward its goal of becoming the world’s largest contract manufacturer of biological medicines. With the smartphone market nearing saturation, Samsung Group, which controls more than 50 companies with interests from TVs...